A vaccine is not only a medical product.
In a crisis, it becomes a diplomatic signal. It tells another country whether it has been remembered or abandoned. It tells a poor country whether global solidarity is real or only spoken at summits. It tells citizens whether science can reach them before fear does. It tells the world which states can convert laboratories, factories, logistics and political will into life-saving power.
This is why vaccine diplomacy has become one of the most important instruments of 21st-century foreign policy.
For India, the lesson is especially powerful. Long before COVID-19, India had already become a central supplier of affordable medicines and vaccines to the world. But the pandemic made that role visible at a strategic level. Suddenly, health manufacturing was not just an industry. It was power. Supply chains were not just commercial networks. They were diplomatic infrastructure. Vaccine exports were not just public health assistance. They were geopolitical credibility.
India’s vaccine diplomacy gave it a stronger global health role because it combined three things that many countries do not possess together: manufacturing scale, developing-world credibility, and the ability to supply at relatively affordable cost.
But this role also comes with responsibility. Vaccine diplomacy can build trust, but it can also lose trust if supplies are disrupted. It can strengthen India’s soft power, but only if backed by quality, transparency and reliability. It can give India leadership in the Global South, but only if India goes beyond symbolic generosity and helps build a fairer global health architecture.
India’s strength begins with manufacturing scale
India’s vaccine diplomacy did not appear suddenly during COVID-19. It rested on decades of pharmaceutical and vaccine-manufacturing capacity.
The Government of India has stated that India accounts for around 60 percent of global vaccine production, making it the largest vaccine producer in the world. It also stated that India is one of the biggest suppliers of low-cost vaccines and the largest provider of generic medicines globally by volume.
This scale matters because global health is not saved by speeches alone. It requires factories, raw materials, trained workers, regulatory systems, cold chains, transport networks and predictable procurement.
India’s vaccine ecosystem includes major manufacturers such as Serum Institute of India, Bharat Biotech, Biological E and others. Serum Institute says it is the world’s largest vaccine manufacturer by number of doses produced and sold globally, producing more than 1.5 billion doses, and that about 65 percent of children in the world receive at least one vaccine manufactured by Serum Institute.
That gives India a form of structural influence. A country that can manufacture at global scale does not merely participate in global health. It shapes access.
Vaccine Maitri turned capacity into diplomacy
During COVID-19, India launched Vaccine Maitri, supplying Made-in-India vaccines abroad through grants, commercial exports and COVAX-linked channels. The Ministry of External Affairs maintained a country-wise vaccine-supply dashboard listing dispatches under grant, commercial and COVAX categories.
By May 2023, the Government of India stated that India had supplied over 298 million COVID-19 vaccine doses to around 100 countries under the Vaccine Maitri initiative.
This was strategically important for three reasons.
First, it allowed India to present itself as a responsible global actor at a moment when many countries were accused of vaccine nationalism.
Second, it strengthened India’s relationships with neighbouring countries, African partners, island states, Latin American countries and other developing nations.
Third, it reinforced India’s image as the “pharmacy of the world” not only in medicine but in emergency public health response.
Vaccine Maitri was not merely charity. It was foreign policy through public health.
The Global South remembers who supplied first
In international relations, timing matters.
A vaccine delivered early carries more diplomatic value than a vaccine delivered after a crisis has peaked. For many countries, especially smaller and poorer states, early vaccine access during COVID-19 was not guaranteed. Wealthy countries signed advance purchase agreements. Supply chains were strained. Export restrictions appeared. COVAX faced shortages. The rhetoric of global solidarity often moved slower than the virus.
India’s early vaccine supplies therefore had symbolic power. They told several countries that New Delhi could act before larger global systems fully delivered.
This is why vaccine diplomacy is different from ordinary aid. Food aid, credit lines and infrastructure projects matter, but vaccines during a pandemic enter the emotional memory of societies. They are associated with survival, fear, gratitude and vulnerability.
A country that provides vaccines in a crisis is not simply sending cargo. It is entering another country’s public memory.
Vaccine diplomacy strengthens India’s neighbourhood policy
For India, vaccine diplomacy has special significance in South Asia and the Indian Ocean.
India’s neighbourhood is not just a geographic space. It is a public-health ecosystem. Disease does not stop at borders between India, Nepal, Bangladesh, Bhutan, Sri Lanka, Maldives and Myanmar. Migration, trade, tourism, religious travel, labour movement and porous borders make health interdependence unavoidable.
This means India’s own health security improves when neighbouring countries are better protected.
Supplying vaccines to neighbours is therefore both humanitarian and strategic. It reduces regional vulnerability, builds goodwill, limits the space for rival powers, and shows that India can provide public goods in its immediate region.
But regional vaccine diplomacy must be consistent. Neighbours do not only judge intention; they judge reliability. If India wants to be seen as the first responder in South Asia, it must maintain emergency production capacity, export predictability, technical cooperation and regional health surveillance partnerships.
Neighbourhood leadership is not declared. It is demonstrated during crises.
COVAX exposed both India’s importance and the risk of dependence
India’s manufacturing role became central to the COVAX facility, the global mechanism created to support equitable access to COVID-19 vaccines.
Gavi stated in March 2021 that Serum Institute of India was contracted to provide COVAX with the SII-licensed and manufactured AstraZeneca-Oxford vaccine, known as Covishield, for 64 lower-income economies participating in the Gavi COVAX Advance Market Commitment, alongside commitments to the Government of India.
This showed India’s importance. Without Indian production, vaccine access for many lower-income countries would have been even more difficult.
But it also exposed a vulnerability. When India faced its devastating domestic COVID wave, vaccine exports were disrupted and COVAX deliveries were delayed. That was understandable from India’s domestic perspective: any government facing a severe public-health emergency would prioritize its own citizens. But for recipient countries, the delay revealed the risk of relying too heavily on one manufacturing geography.
This is the central paradox of India’s vaccine diplomacy. India’s scale makes it indispensable. But the world also needs diversified vaccine production so that one country’s domestic crisis does not become everyone else’s supply crisis.
India can turn this lesson into leadership by helping other regions build manufacturing capacity rather than insisting on permanent dependence.
Vaccine diplomacy must evolve from supply to partnership
The first phase of vaccine diplomacy was about supplying doses.
The next phase must be about building capacity.
The Global South does not need to remain permanently dependent on emergency donations from a few vaccine-producing countries. It needs regional manufacturing, regulatory capacity, quality-control systems, technology transfer, cold-chain logistics, trained scientists, procurement institutions and sustainable financing.
India is well placed to support this transition.
It can help African, Asian and Latin American partners through joint ventures, training, licensing, regulatory cooperation and affordable technology partnerships. It can support vaccine research suited to developing-country needs. It can work with WHO, Gavi, UNICEF and regional bodies to reduce the gap between vaccine discovery and vaccine access.
This would make India’s health diplomacy more durable. A donated vaccine builds goodwill for a moment. A manufacturing partnership builds influence for decades.
India’s affordability advantage matters
Global health is not only about innovation. It is also about price.
A vaccine that exists but remains unaffordable does not solve a public-health problem for low-income countries. The developing world needs vaccines that are scientifically credible, quality-assured and affordable at scale.
India’s pharmaceutical model has historically been important because it focuses on cost-sensitive production. This is one reason Indian medicines and vaccines matter so much in global public health.
Recent developments show how this role continues beyond COVID. In 2025, Gavi and UNICEF signed a deal with Serum Institute of India to reduce the price of the R21 malaria vaccine by 25 percent, from about $4 to $2.99 per dose. Reuters reported that the lower price would allow Gavi and UNICEF to fund 30 million more doses and reach an additional 7 million children over five years.
This is vaccine diplomacy in its deepest form. It is not only about sending doses during a crisis. It is about changing the economics of access.
If Indian manufacturers can make important vaccines cheaper without compromising quality, India becomes central to global health equity.
Indigenous vaccines strengthen strategic autonomy
India’s vaccine diplomacy becomes stronger when it is not merely manufacturing foreign-developed products, but also developing and scaling indigenous vaccines.
COVID-19 saw India produce both licensed and domestically developed vaccines. Beyond COVID, India’s vaccine innovation is expanding into areas such as HPV, malaria, adult immunization and other public-health priorities.
India’s first indigenous HPV vaccine, Cervavac, developed by Serum Institute in collaboration with Indian public institutions, is an example of how domestic vaccine innovation can address both Indian and global needs. Reports in 2024 described Cervavac as a lower-cost Indian-made HPV vaccine aimed at preventing cervical cancer, a major cause of death among women in low- and middle-income countries.
This matters because vaccine diplomacy built only on manufacturing contracts can be vulnerable to foreign intellectual property, technology access and supply-chain control. Indigenous R&D gives India greater strategic autonomy.
The future of Indian vaccine power will depend not only on making doses, but on discovering, developing and regulating them.
Quality is the foundation of trust
Vaccine diplomacy depends on trust.
No country accepts vaccines only because they are cheap or politically friendly. It must trust the safety, quality and regulatory credibility of the product. India’s global role will therefore depend on maintaining high manufacturing standards, transparent quality systems and strong pharmacovigilance.
This is where India must be careful. The phrase “pharmacy of the world” is powerful, but it also creates scrutiny. Every quality failure in pharmaceuticals or vaccines can damage India’s reputation far beyond one company or product.
As India expands global vaccine influence, regulatory strength must become a diplomatic priority. India needs world-class inspection systems, rapid response to quality concerns, transparent recall mechanisms, strong clinical-trial ethics, and alignment with global standards.
In vaccine diplomacy, reputation is as important as capacity.
A country can export doses. But it must earn confidence.
Vaccine diplomacy is also geopolitical competition
Health cooperation sounds humanitarian, but it is also geopolitical.
During COVID-19, vaccines became part of competition among major powers. Countries watched which vaccines arrived, from whom, with what terms, with what publicity and with what political expectations. Vaccine brands became associated with national reputation. Donations became diplomatic messaging. Delays became strategic disappointment.
China, Russia, the United States, European countries and India all used health diplomacy in different ways. Some offered doses. Some offered financing. Some emphasized technology. Some used vaccine access to strengthen political relationships.
India’s advantage was different. It could speak as a developing country supplying other developing countries. This gave it a credibility that many advanced economies lacked.
But geopolitical advantage cannot be taken for granted. If India wants to remain a trusted health partner, it must avoid making vaccine diplomacy appear transactional or overly symbolic. The strongest form of soft power is not publicity. It is dependability.
The pandemic agreement makes vaccine equity a permanent issue
The global vaccine debate did not end with COVID.
The WHO Pandemic Agreement, adopted in May 2025, places equity, local production, supply-chain cooperation and pathogen access and benefit-sharing at the centre of future pandemic preparedness. WHO describes the Pathogen Access and Benefit-Sharing system as a central pillar intended to ensure rapid sharing of pathogens with pandemic potential and fair, timely sharing of benefits such as vaccines, diagnostics and therapeutics based on public-health need.
This debate is crucial for India.
India is both a major supplier and a voice of the Global South. It has an interest in rapid access to pathogen data, but it also has an interest in fair sharing of benefits. It wants innovation, but also affordability. It wants manufacturing strength, but also global equity.
India can therefore play a bridge role between the developed world’s technology and the developing world’s access needs.
The future of vaccine diplomacy will not be only about emergency generosity. It will be about the rules that decide who gets vaccines first when the next pandemic begins.
Vaccine diplomacy expands India’s soft power
Soft power is often associated with culture, films, yoga, cuisine, democracy, diaspora and civilizational heritage. Health diplomacy adds a harder edge to soft power because it connects goodwill with survival.
When India supplies vaccines, trains health workers, supports digital health systems or helps build manufacturing capacity, it creates a practical form of goodwill. It shows capability, not just identity.
This is especially valuable in Africa, Latin America, Southeast Asia and the Pacific, where development partnerships are increasingly competitive. Countries do not want lectures. They want affordable solutions, timely delivery and respectful partnerships.
India’s vaccine diplomacy can strengthen its position as a development partner that understands scarcity because India has experienced scarcity itself.
That is an important diplomatic asset.
But vaccine diplomacy cannot hide domestic health weaknesses
There is also a warning.
A country cannot build lasting global health leadership while neglecting domestic public health. International vaccine diplomacy is strongest when supported by credible domestic health outcomes.
India must therefore strengthen immunization coverage, public-health surveillance, primary healthcare, cold-chain logistics, adverse-event monitoring and public communication at home. Its domestic vaccination systems must become models of scale and trust.
The world respects a country that helps others. It respects even more a country that demonstrates competence internally.
India’s global health role must therefore be built on both external supply and internal reform.
Digital health can deepen vaccine diplomacy
India’s vaccine diplomacy can be strengthened by its digital public infrastructure experience.
During COVID-19, India used digital platforms for vaccination registration, certification and tracking. Digital vaccine certificates became part of mobility, administration and public-health coordination. In future, India can share not only vaccines but digital health tools, provided they are adapted to local conditions and include privacy safeguards.
This is important because vaccine access is not only about manufacturing. It is also about identification, appointment systems, last-mile delivery, stock management, certification, adverse-event reporting and public communication.
A country may receive doses but fail to distribute them efficiently. Digital systems can help, but only if they are inclusive. Poor internet access, language barriers, documentation gaps and digital literacy must be considered.
India’s digital health diplomacy should therefore avoid exporting technology as a one-size-fits-all product. It should offer adaptable public-health infrastructure.
The next frontier is routine immunization
Pandemic vaccines receive attention because crises are dramatic. But routine immunization saves lives quietly every year.
Measles, polio, diphtheria, tetanus, pertussis, hepatitis, rotavirus, pneumococcal disease, HPV and other vaccine-preventable diseases remain major public-health challenges in many countries. Vaccine diplomacy should not begin and end with pandemics.
India can play a major role in strengthening routine immunization across the Global South through affordable supply, technical training, cold-chain support and public-health partnerships.
UNICEF says it leads global vaccine supply work with partners, supplying vaccines to reach 45 percent of the world’s children under five years of age. Indian manufacturers are deeply connected to this global immunization ecosystem.
This is where India’s long-term influence lies. Emergency diplomacy gets headlines. Routine vaccine supply builds generational trust.
Vaccine diplomacy must include women’s health
A mature vaccine diplomacy strategy must also pay attention to gendered health burdens.
Cervical cancer, maternal immunization, adolescent vaccination and access to HPV vaccines are not peripheral issues. They shape women’s health, family welfare and public-health equity in the developing world.
India’s lower-cost HPV vaccine potential could be significant for countries where cervical cancer remains under-screened and under-prevented. The Guardian reported that Cervavac was expected to be provided through India’s government system at much lower cost than expensive foreign versions, with Serum Institute planning to scale production.
If India can help reduce the cost of vaccines that protect women and girls, its vaccine diplomacy will gain a deeper social dimension.
Global health leadership should not only respond to pandemics. It should prevent avoidable deaths that never become breaking news.
Health diplomacy must be transparent
Vaccine diplomacy can sometimes become propaganda if it is not transparent.
Countries should know whether supplies are grants, commercial sales, concessional arrangements or multilateral deliveries. Public communication should avoid exaggeration. Recipient-country dignity should be respected. Donations should not be presented as acts of superiority.
The Ministry of External Affairs’ Vaccine Maitri dashboard was useful because it categorized vaccine supplies across grant, commercial and COVAX channels. That kind of transparency matters because it helps distinguish humanitarian support from normal trade.
The best vaccine diplomacy is not theatrical. It is clear, reliable and respectful.
India should build a Global South vaccine compact
India’s next step should be more ambitious than one-off supply.
It should help create a Global South vaccine compact built around affordable access, regional manufacturing, emergency stockpiles, regulatory cooperation and technology partnerships.
Such a compact could include African Union institutions, ASEAN partners, Latin American countries, small island developing states, WHO, Gavi, UNICEF and development banks. India could offer training, licensing partnerships, regulatory support and supply commitments.
The goal should not be Indian dominance. The goal should be distributed resilience.
If the next pandemic begins, the Global South should not again wait at the back of the queue.
India can help change that.
Vaccine diplomacy and strategic autonomy
India’s vaccine role also supports its larger foreign-policy doctrine of strategic autonomy.
A country that controls essential health manufacturing is less vulnerable to pressure. It can protect its own citizens and support partners. It can negotiate from strength. It can contribute to multilateral systems without becoming dependent on them.
But strategic autonomy should not mean isolation. In vaccines, no country is fully self-sufficient. Raw materials, research collaboration, clinical data, regulatory recognition, intellectual property, packaging, glass vials, adjuvants and cold-chain systems are global.
India’s best path is not health nationalism. It is trusted interdependence.
India should build resilient domestic capability while remaining deeply connected to global scientific and supply networks.
The lesson from export disruption
A serious article on India’s vaccine diplomacy must acknowledge the difficult moment when India’s domestic COVID crisis disrupted exports.
From India’s perspective, prioritizing domestic vaccination during a deadly wave was politically and morally understandable. A government’s first duty is to its citizens. No foreign-policy ambition can override a national health emergency.
But from the perspective of countries waiting for supplies, the disruption was painful. It revealed the fragility of global dependence on concentrated production.
The lesson is not that India failed as a vaccine power. The lesson is that vaccine diplomacy must be designed with emergency buffers, diversified capacity and clearer contractual expectations.
Reliability is not only about good intentions. It is about systems that survive pressure.
India’s stronger global role must be earned continuously
Vaccine diplomacy has given India a stronger global health role, but that role is not permanent by default.
It must be earned through five forms of credibility.
First, production credibility: the ability to manufacture at scale.
Second, regulatory credibility: the ability to ensure quality and safety.
Third, diplomatic credibility: the ability to supply without humiliating recipients or over-politicizing aid.
Fourth, equity credibility: the willingness to support fair access, not just commercial advantage.
Fifth, innovation credibility: the capacity to develop new vaccines, not only manufacture existing ones.
If India succeeds on these five fronts, it can become one of the central architects of global health security.
Conclusion: vaccine diplomacy is India’s health-power moment
Vaccine diplomacy has changed India’s place in global health.
It has shown that India’s pharmaceutical and vaccine capacity is not merely an economic asset. It is a diplomatic instrument, a humanitarian tool and a strategic capability. It has allowed India to speak to the Global South not only with rhetoric, but with supplies. It has strengthened India’s claim to be a responsible power in a world where health security is now national security.
But vaccine diplomacy should not become self-congratulation.
The world does not need another round of symbolic announcements. It needs fairer access, stronger manufacturing networks, better quality systems, faster emergency response, more affordable vaccines and deeper trust.
India is well placed to lead this agenda because it understands both sides of the global health equation. It is a major producer, but also a country with developing-world public-health challenges. It knows the pressure of scale, affordability and inequality. That gives its leadership a credibility that purely rich-country health diplomacy often lacks.
The next pandemic will test whether the world has learned from the last one.
When that moment comes, vaccines will again become more than vials. They will become instruments of trust, survival and power.
India’s task is clear: turn vaccine diplomacy from a crisis response into a permanent pillar of global health leadership.
That is how India can move from being the pharmacy of the world to becoming one of the guardians of global health security.
